1 / 52

Inserm French National Institute of Health and Medical Research

Inserm French National Institute of Health and Medical Research. Created in 1964 from the National Institute of Hygiene and Hospital Research. Working through the Ministries for Research and Health. Inserm : key figures. 335 Inserm laboratories 19 research centers.

wtoledo
Download Presentation

Inserm French National Institute of Health and Medical Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inserm French National Institute of Health and Medical Research • Created in 1964 from the National Institute of Hygiene and Hospital Research • Working through the • Ministries for Research and Health

  2. Inserm : key figures 335 Inserm laboratories 19 research centers 41 Clinical Investigation Centers (CIC) Budget 2007 : 700 M€ Total staff: 13 000 (2 500 physicians) of which 4900 Inserm employees: 2100 scientists and 2800 technical staff (62% of total budget dedicated to salaries) An active patent portfolio of 572 families 374 French and foreign firms are partners of Inserm 56 start-up companies based on Inserm technology

  3. What is Inserm ? • The French performing research organisation entirely dedicated to Biomedical &Clinical research and Public Health • All fields of research are covered in these domains • 90% of the 365 research units are located in University hospitals • Research units with 8 years mandate with mid-term (4 year) evaluation. Stringent evaluation • Investigator- driven projects - AVENIR programme • Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.

  4. The Inserm performance about:blank

  5. Bottom-up initiatives: selection based on quality and innovation Networks focused on major public health issues: “National Research Programs”: Diabetes, Cardiovascular, Hepato-Gastro- Enterology Bone and joint diseases, endocrinolgy and reproduction etc…. Organization

  6. Public health Infectious diseases and microbiology Handicap Nutrition 5.1% AIDS 7.5% 4.8% Hepatitis 3.7% (without Aids and Hepatitis) 3.1% Diabetes 8.3% 2.6% Cardiovascular diseases Bone and Joint Diseases 9.1% 2.2% Genetic diseases Neurosciences 10.5% 20.6% of which 9.3% for neurologic 16.8% disorders Cancer 17.1% Immunology Research laboratories being often involved in more than one domain, the overall distribution is over 100 %

  7. Hospitals Universities Industry National research & Public health agencies International scientific community Research organizations CNRS, CEA, Inra, Inria, IRD, Pasteur Institute, Curie Institute Scientific & medical societies, Patients associations, Foundation, Charities

  8. Inserm : creation of research centers • Objectives and main characteristics: • Critical mass (100 to 300 staffs), • Mutualisation and Integration • International visibility, Attractiveness • Assessment criteria: • Scientific excellence • Quality of the management : Governing structure, mutualised administration & management • Technology transfert and research outcomes • Sharing of technical facitilies • Coordination of scientific events and programmes • Implementation of research training programmes • International scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)

  9. 19 Research Centers in 2007 Some exemples: 1- Paris 6, Pluri-thematic 2- Paris 6, Neurophysiology 4- Paris 5, Pluri-thematic 5- Créteil, Pluri-thematic 6- Lilles, Pluri-thematic 7- Dijon, Cancer/Nutrition 8- Bordeaux, Neurophysiology 9- Grenoble, Neurophysiology 10- Grenoble, Cancer 11- Toulouse, Pluri-thematic

  10. Physiopathologie et thérapie des déficits sensoriels et moteurs Director : Christian Hamel • Partners • Montpellier 1 et 2 Universities • Montpellier University Hospital • Inserm • Thematics • Pathophysiological studies and therapeutic • innovation in neurosciences • Sensory diseases : auditio, vision, propriception • nociception • Facilities • Histology • Cellular imaging • Human neurogenetics • Experimental pharmacology • Cellular and animal models • Technology transfer • Public-private Partnerships • patents Inserm Unit 583 5 teams 108 staffs Montpellier www.inmfrance.com

  11. Institut François Magendie Director : Pier Vi Piazza • Partners • Bordeaux 1 University • Bordeaux University Hospital • Inserm Inserm Unit 862 8 teams 100 staffs Bordeaux 3 Avenir program • Thematics • Addictiopn physiopathology • Neurogenesis and physiopathology • Physiology of the neuro-endocrinal systems • Synaptic plasticity and medullar neuronal netkwork • physiopathology • Facilities • Small animals • Non human primate • Motricity • IRM • Biochemestry • Technology transfer • Public-private Partnerships

  12. Département de Recherche en Cancérologie DReC Director : Marc Bonneville Inserm Unit 601 7 teams 145 staffs Nantes • Partners • - Inserm • Nantes University Hospital • Nantes University • Thematics • Lymphocyte and dendritic cells • Cytokines and receptors • Conventional and non-conventional immunity, • Oncology, virology • Apoptosis and tumor progression • Radiopharmaceutics • Facilities • Quantitative PCR • Cellular imaging • Recombinant proteins • Histology, morphology • Technology transfer • 14 patents • Public-private Partnerships www.u601.nantes.inserm.fr

  13. Institut de Médecine Moléculairede Rangueil I2MR Director : Angelo Parini Inserm Unit 858 15 teams 156 staffs Toulouse • Thematics • Obesity, heart and kidney pathologies • Vascular biology, inflammation and diabetes • Epithelial cancers, angiogenesis and signalling • Facilities • Biotherapy • Proteomics • Histo-morphology • Genomics and molecular biology • Fonctional exploration • Zootechnics • Partners • - Inserm • Toulouse University Hospital • Paul Sabatier University in • Toulouse • Technology transfer • Public-private Partnerships

  14. Centre de recherche Cardiovasculaire Inserm CRCIL Director : Bernard Lévy Inserm Unit 689 5 teams 114 staffs Paris • Partners • Inserm • Paris University Hospital • Paris 7 University • Thematic • Cardiovascular • Angiogenesis • Facilities • Animals • Cell Culture • Cytometry • Small animal fonctional • exploration • Technology transfer • 6 patents • Public-private Partnerships

  15. Director : Marc Laburthe Inserm Unit 733 11 teams 160 staffs Paris • Partners • Inserm • Paris University Hospital • Paris 7 University • Thematics • Gastroenterology • Inflammation • Receptors • Facilities • Quantitative PCR • Cellular imaging • Small animal Fonctional • explorations • Histology, morphology • Technology transfer • 3 patents • Public-private Partnerships

  16. Director : Joël Bockaert • Partners • Inserm • Montpellier 1 et 2 Universities • Montpellier University Hospital • CNRS • Thematics • Cancer • Cardiovascular • Genetic and cellular therapies • Metabolism, endocrinology, nutrition • Human health • Brain Inserm Unit 661 5 departments 159 staffs Montpellier 1 Avenir program • Facilities • Transcriptomics • Proteomics • Photonic Imaging • Pharmacology • Technology transfer • 5 patents • Public-private Partnerships • * Sanofi • * Pfizer • * …. www.igf.cnrs.fr

  17. Director : D.Moras • Partners • - Inserm • Louis Pasteur University • CNRS Inserm Unit 596 7 departments 550 staffs Strasbourg 3 Avenir programs • Thematics • Molecular pathology • Developmental and physiological gentics • Fonctional genomics • Cellular biologie and signal transduction • Molecular neurobiology • Facilities • Cellular imaging • DNA microarray platform • Monoclonal Antibody • Structural biology • Bio-informatic • Protéomics • Technology transfer • > 20 contrats with industries • Public-private Partnerships www-igbmc.u-strasbg.fr

  18. Research infrastructures • National Genomic Research Consortium:CNRG • National Sequencing Center • National Genotyping Center • Regional Genopoles Core Facilities • Biosafety-level 4 laboratory • Local and regional technological plateforms • Clinical Research Infrastructures

  19. Main Inserm’s priorities « Researchers » : Careers, Training & Mobility To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach To establish Inserm in a European and International context To develop public/private partnerships

  20. Career tracks at Inserm • Junior, temporary contract (5 years with a 3-year intermediate evaluation), high level (research director) contracts • Avenir program • European programs: EURYI, ERC • Permanent positions for senior scientists

  21. AVENIR Programme • Eligibility: Young scientists with permanent or temporary position, clinicians • Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities • Each successful candidate is allocated: • A yearly budgetof 60 K euros • Minimum lab spaceof 50 m2 • Personnel: 1 post-graduate collaborator and 1 graduate student • Each successful young scientist receivesa salary for 5 years

  22. Programme dedicated to “Frontier research” Targeted to: Young researchers Starting Independent Research Grant Advanced researchers Advanced Investigator Research Grant 100 to 400 K€/year up to 5 years Attractive research environment at Inserm: 335 Research units incl. 19 Research centers Performing research infrastructures incl. 41 Clinical Reserach Centers Public-Private partnerships - Innovation Salary up to 7k€ monthly Potential tenure career track ERC - European Research CouncilThe 7th FP - EU

  23. Interface contracts: General principles • Based on : • apermanent position + temporary, 3-5 year contracts • To reinforce interactions with partners and mobility • Hospitals: clinical research, medical issues • Health agencies: health policy issues • Universities: teaching, making scientific information available to the society • Industry: technological transfer and valorisation • European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)

  24. Hospital University Industry Tenured scientists International institutions Sanitary Agencies « Internal » Inserm Interface contracts for Inserm scientists : Tenure position + 3-5 year contracts: " 2/3 – 1/3 "

  25. InterfaceContract grants for MDs • Reinforce research activities of clinicians and university research assistants and professors • 3-5 year contracts for clinicians : assistant professors and • professors, university employees • Grant paid by Inserm to hospitals and universities to be used for : • - clinical and teaching activities: temporary positions • - financing research activities

  26. Interface contracts for MDs INSERM HOSPITAL INSERM UNIVERSITY

  27. Joint post-doctoral career track Inserm-NIH • 3-year post-doctoral positions in NIH: Join selection by Inserm and NIH • Evaluation at the end of post-doctoral fellowship • Junior, 5-year Inserm contract • Tenure: Inserm, CNRS, University, industry etc ..

  28. The School of Inserm A 3-year Theoretical and Practical Education which leads to a Master’s • First year of Inserm School - Second year of Medical School : • Special School Intensive Training Session in February • June: Competitive Exam • Second year of Inserm School - Third year of Medical School • 6 month full time Research Clerkship in an Inserm Research Laboratory • Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree

  29. Clinical research and Translational research strategy

  30. Clinical trials Inserm Inserm Inserm Proof of concept Phases I-IIa Biotherapy Preclinical studies : Proof of concept Basic Research Phase IV Cohorts Phases IIb-III [CRC]

  31. Clinical research infrastructures

  32. Finland FinnCRIN European Clinical Research Infrastructures Network, co-ordinated by INSERM: Pan-European infrastructure providing services to the preparation and the conduct of multinational clinical studies, with GMP facilities for biotherapy Sweden SweCRIN Denmark DCRIN Ireland ICRIN UK UKCRN EORTC Germany KKS EFGCP Austria ATCRIN France Inserm Hungary HECRIN Switzerland SCRN Spain SCReN Italy IRFMN & CIRM National networks of Clinical Research Centres / Clinical Trial Units

  33. Network of Biological Resources Facilities Cohorts of Patients • Science Case: • A European network to coordinate European Scientific programs and policies • Clinical data and follow-up of patients and Healthy volunteers • Innovative targets, biomarkers, clinical studies • Technology transfer, dissemination of knowledge, valorisation • Technical case: • Repositories for qualified biological samples (DNA, RNA, proteins,…), coupled to clinical data. • Providers/distributors of samples within scientific project objectives • Development of QA standards for European BRCs • To store samples for the future (heritage) • Distributed facilities / centralised database

  34. EU approach for of GMP Facilities • Needs : to develop innovative “non-commercial” clinical trials - Lack of specific financial support • Science Case: • Reinforcing clinical research and translation of basic research to therapy • Production and evaluation of innovative therapeutic and diagnostic agents : biomarkers and biotherapy / regenerative medicine : cell therapy, gene therapy, tissue engineering • Technical case: • Production of new therapeutic/diagnostic agents from biotechnologies • Products for Cell and Gene therapy • Good Manufacturing Practices (GMO dissemination regulation), in line with national legislation, able to cooperate across the borders • Direct links with Clinical Research Centres (CRC - ECRIN)

  35. IMI : Innovative Medicines for Europe European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way. Inserm is the French representative in the Member states contact Group of IMI

  36. Regional clusters Canceropoles, other thematic poles (Neuropole, …) Competitivityclusters (Industry) Regional poles for research in Neurosciences, etc.

  37. Nutrition Santé Longévité Innovations thérapeutiques Medicen Imaging, Cancer, Biotehrapy, Neurosciences Atlantic Biothérapies International Lyonbiopôle Virology Qualitropic National Prod’Innov Emergent Réunion Cancer Bio Santé Cancer Bio Santé Orpheme Nutrition Competitivity Clusters 67 created clusters 7 involving Inserm units

  38. The European policy of Inserm

  39. The main axes • EU Prospectives (ESF-EMRC, EUROHORCS,etc.) • Participation in European programmes : RTD FP & Public Health FP • Infrastructures - ESFRI (ECRIN, …) • Researchers’ mobility within EU programmes and • Bilateral actions: Common Research projects - Associated laboratories - Joint-units abroad

  40. Multilateral cooperations’ actions Participation to the European Research and Public Health programmes Inserm and The 6th Framework Programme of the EU • around 166 EU research projects • 26 in coordination • (success rate: 50% last FP6 calls) • (preliminary data - April 2007) Inserm and The 7th Framework Programme of the EU (2007 - 2013)

  41. European Mobility of Researchers « Towards a European Career Track » • International Cooperation Contracts (up to 4 years) • Salary paid by “home” institution + additional salary paid by “host” institution • Reciprocal, bi-directional => Marie Curie « Co-fund » Programme (FP7) • Joint Post-doctoral training contracts 2 phases, commitment for a contractual recruitment when they return, bidirectional call for application • Prospectives towards Internationalisation of School of Inserm

  42. Joint post-doctoral career track • 3-year post-doctoral positions in host institutions: Joint selection with Inserm • Joint calls under preparation with European institutions (ICL, Univ. Dundee, Porto…) • Evaluation at the end of post-doctoral fellowship • Junior, 5-year Inserm contract • Tenure: Inserm, CNRS, University, industry etc ..

  43. Cooperations between Inserm and Czech Partners (1) 20 cooperation projects undertaken since 2000=> more than 100 common publications (38 in 2006) Main cities: Prague, Olomuc, Brno Main Partner Institutions : Academy of Sciences of the Czech Republic, Charles University Prague, etc. Main thematic areas : Neurosciences, Microbiology, Nutrition, Molecular Biology, Toxicology etc. 3 Czech Post-docs, Researchers and Fellows within Inserm's research units in 2006 43

  44. Cooperations between Inserm and Czech Partners (2) • European Associated Laboratory (EAL) “Clinical Research on Obesity” D. Langin, Toulouse – V. Stich, Charles University Prague • In the frame of the 6th EU Framework programme : 23 European research projects mainly in the LSH priority : (7 NoEs - 12 IPs - 4 STREP) - 3 of them involved the EAL • Future collaborations within the FP7 : • Health priority, IMI, Infrastructures (ECRIN, BRCs) 44

  45. Bilateral cooperations’ tools: Associated Laboratories and Inserm’s Units abroad • Scientifically driven • 8 years mandate with mid-term evaluation • Synergies: competencies and facility access • Co-funded by Inserm and Associated partner • Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts) • Institutional “label” • Leverage effect for additional funding

  46. European Associated Laboratories (LEA) • Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles) • Lille : M. Capron U547 / Brussels : M. Goldman (IMI) • Toulouse : AC Prats U589 / Dundee : JC Bourdon (Univ. Dundee) • Bordeaux: A. Bikfalvi E 113 / Milan: L. Bello (Univ. Degli Stuli) • Nice: G. Meneguzzi U 634 / Rome: G. Zambruno (IDI-IRCCS) • Villejuif: D. Samuel U 785 / Rome: M. Levrero (Univ. La Sapienza) • Montpellier: K. Ritchie U 888 / London: G. Thornicroft (King’s College of London) • Strasbourg: T. Baumert U 748 / Freiburg: H. Blum (Univ. of Freiburg) • Villejuif: T. Moreau U 780/ Barcelona: J. Antό (PRBB, IMIM-CREAL) • Bordeaux: L. Bordenave U 577 / Porto: M. Barbosa (IBMC, INEB) Glasgow Dundee • Joint Research Unit in Europe: • Université de Glasgow / C. Doerig U609 • DKFZ / J. Rommelaere U701 London Heidelberg Brussels Prague Freiburg Milan Barcelona Porto Rome

  47. Montreal Laval Montréal Los Angeles Seoul Beijing New York Haïfa Tokyo Rabat Wuhan Irvine Pittsburgh Kyoto Nanjing Dallas Shanghai Doha Guangzhou Singapour Rio de Janeiro INSERM Unit Associated Laboratory In preparation Buenos Aires

  48. Inserm’s private subsidiary Created in 2001, funded up to €4,5 million 60 people with scientific/industrial background Missions: Drive value creation from Inserm research Allow an efficient partnering with the Industry Ensure a fair economic return towards Inserm Contribute to economic development Inserm Transfert

  49. Development of services covering the whole technology transfer process : Detection of inventions / “coaching” Protection of inventions & follow up / intellectual property management Pre-technology transfer / Applied and Translational Research Technology Transfer, collaborative and R&D agreements Preclinical Development / Proof of Concept development Industrial Partnerships / Clinical trials development International and European projects management Biotech start up coaching and funding (pre seed fund Inserm Transfert Initiative) Legal and financial expertise Proximity between both scientific and industrial communities for a best partnership development Inserm Research Detection of Inventions Intellectual Property License Biotech start-up Integrated Technology Transfer Skills“From the bench to the partnering and the license”

  50. Valorisation CIC Sourcing Inserm Transfert: Bridging the gap between Science and Business PARTNERS INSERM International Projects L e g a l F i n a n c e Grants Consortium A D R R E S E A R C H NewCo Creation Seed Fund Spin-Off T E A M S Business Devpt • Industrial • Partnership • Collaboration • Licence Intellectual Property INNOVATION KNOW HOW

More Related